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Renal vasoconstriction during inhibition of NO synthase: Effects of
dietary salt. Since dietary salt loading enhances nitric oxide (NO)
generation in the kidney, we investigated the hypothesis that changes in
salt intake have specific effects on vascular resistance in the kidney
mediated by the L-arginine-NO pathway. We contrasted changes in renal
and hindquarter vascular resistances (RVR and HQVR) in anesthetized
rats during intravenous infusions of graded doses of the NO synthase
inhibitor N°-nitro-L-arginine methyl ester (L-NAME). Groups (N = 8 to
10) of rats were maintained on a high salt (HS) or low salt (LS) diet for
two weeks. Compared to those on LS, rats on HS had a greater increase
in mean arterial pressure (AMAP; +32 4 vs. +22 3%; P 0.05) and
RVR (+ 160 17 vs. +83 10%; P < 0.005) and a greater fall in renal
blood flow (zRBF; —47 3 vs. —32 4%; P < 0.01); changes in HQVR
were similar in the two groups. The enhanced RVR response to L-NAME
in HS rats could not be ascribed to the higher renal perfusion pressure
(RPP) since it persisted in rats whose RPP was controlled by adjustment
of a suprarenal aortic clamp. Changes in RVR with an NO donor (SIN-i)
were similar in HS and LS rats. L-NAME reduced plasma renin activity in
both HS and LS rats. After inhibition of ACE with captopril, or of
angiotensin II type I (AT1) receptor with losartan, the increase in RVR
with L-NAME remained greater in HS than LS rats. In conclusion, an
increase in dietary salt potentiates the renal vascular response to L-
NAME. This effect is specific for the kidney and cannot be ascribed to
changes in NO responsiveness or RPP or to effects of Ang II generation
or action on AT1 receptors.
Generation of nitric oxide (NO) from L-arginine by nitric oxide
synthase (NOS) leads to vasorelaxation of renal and systemic
blood vessels [1—4]. Micropuncture and microperfusion studies in
vivo have disclosed a functional role for NO as a signalling
molecule between the macula densa (MD) and the afferent
arteriole [5]. This MD-derived NO vasodilates the afferent arte-
riole and counteracts vasoconstrictor stimuli generated by the
tubuloglomerular feedback (TGF) response [5]. Dietary salt load-
ing enhances the renal production of NO, as indexed by the
excretion of NO2 and NO3 and cyclic guanosine monophosphate
(cGMP) [6]. Since TGF is a specific renal response, the first aim
of these studies was to examine the hypothesis that there is a
specific renal vasodilator pathway mediated by L-arginine-derived
NO that is activated by dietary salt loading.
Some investigators have shown that increases in renal vascular
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resistance (RVR) during low-dose infusions of N°-nitro-L-argi-
nine methyl ester (L-NAME) are blunted or prevented by ma-
neuvers that decrease the plasma renin activity (PRA) or block
angiotensin II (Ang II) generation or action [3, 7—9]. Indeed, since
a three day infusion of L-NAME into conscious dogs at sub-
pressor doses increases the PRA, it has been suggested that the
increases in renal vascular resistance (RVR) induced by inhibition
of NOS can be mediated by increases in renin release and Ang II
generation [10]. However, short-term infusions of L-NAME pro-
duce variable effects on PRA or renal tissue Ang II concentration,
depending upon changes in renal perfusion pressure or renal
nerve activity [3, 11]. Moreover, some studies have failed to detect
any blunting of the RVR response to inhibition of NOS by
blockade of the renin-angiotensin system [12—14]. Indeed, the
conclusion that Ang II mediates or promotes the response to NOS
inhibition is hard to reconcile with the finding that a high salt diet
which suppresses the renin-angiotensin system increases renal NO
generation [6]. Therefore, the second aim of these studies was to
investigate the role of Ang II generation and action on type I
(AT1) receptors in the regulation of RVR by the L-arginine-NO
pathway in rats adapted to high or low levels of dietary salt intake.
A preliminary account of this work was presented at the
American Society of Nephrology meeting in Boston and was
published (J Am Soc Nephrol 4:547, 1993).
Methods
Animal preparation
Male Sprague-Dawley rats (250 to 350 g) were maintained on
standard rat chow (Rodent Laboratory Chow 5001, Ralston-
Purina Co., St. Louis, Missouri, USA; Na content 0.3 g 100 g')
until 14 to 17 days prior to study when they received a special
chow with a low salt content (LS; Na content 0.03 g 100 g1;
Tekiad Inc., Madison, Wisconsin, USA) or the same chow with a
high salt content (HS; Na content 6 g 100 g'). On the day of
study, they were anesthetized with an intraperitoneal injection of
mactin (100 mg kg 1; BYK Gulden, Konstanz, Germany) and
maintained at 37°C on a servo-controlled heated rodent operating
table. Both jugular veins were cannulated; one cannula was used
for infusion of albumin (6g. dl; Sigma Chemical Co., St. Louis,
Missouri, USA) dissolved in 0.154 M NaCI solution• (for HS rats)
or 5 g 100 g' dextrose solution (for LS rats). The other was used
to infuse drugs dissolved in 0.154 M NaC1 that were infused
continuously at 2 ml h . The left carotid artery was cannulated
for blood sampling and recording of mean arterial pressure
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(MAP) from the electrically damped output of a pressure trans-
ducer (Statham model P23, Gould, Oxnard, California, USA).
The abdomen was opened via a midline incision. The left renal
artery was cleaned and a transit time blood flow probe (1RB)
placed around it and connected to a two channel transit time
blood flow meter (Transonic Systems Inc., Ithaca, New York,
USA). The terminal aorta was cleaned and a second blood flow
probe (2SB) was placed around it and connected to the second
channel of the transit time blood flow meter.
After 30 minutes for equilibration, baseline measurements of
MAP, renal blood flow (RBF) and hindquarter blood flow
(HQBF) were made at five minute intervals for 15 minutes. These
values were averaged for the basal data, Thereafter, rats received
an intravenous infusion of either vehicle (Group la) or N°-nitro-
L-arginine methyl ester (L-NAME) (Sigma Chemical Co.) (re-
maining groups) in graded doses (3.7, 37 and 370
nmol kg' min1) or the maximally effective dose of 11.11
mol kg1 min. Each infusion or dose was given for 45
minutes. After 20 minutes of infusion, the MAP, RVR and
HQVR had reached maximal values; therefore, data for analysis
were taken at the 20 minute period of L-NAME or vehicle
infusion.
After the maximal dose of L-NAME, rats of group lb received
graded intravenous bolus injections of the NO donor compound
3-morpholino-sydnonimine hydrochloride (SIN-i; Cassella AG.,
Frankfurt, Germany) at 9.7, 97, 970, 9700, and 97,000 nmol kg—1;
measurements of MAP, RBF and HQBF were made at five
minute intervals after each bolus injection. Ten minutes after
SIN-i injections, the MAP, RVR and HQVR had reached
minimal values; therefore, data for analysis were taken at the 10
minute period.
At the completion of the study, the animals were euthanized
and the kidneys removed and weighed.
Measurements of renal and hindquarter blood flow rates
The transit time blood flow technique used in this study was
evaluated in our laboratory. The probes used to measure RBF and
HQBF were calibrated in vitro using isolated vessels. The transit
time measurement of blood flow was quite accurate across a wide
range of flows and blood hematocrit values. An in vivo validation
was undertaken by comparing the transit time blood flow mea-
surements of RBF with simultaneous measurements of RBF from
the clearance and renal extraction of [14C]-paraminohippurate.
There was a good correlation between the two methods (r = 0.84;
N = 74; P < 0.0001) without a systematic deviation [15]. Blood
flow probes were calibrated at monthly intervals. Zero blood flow
was determined during periods of occluded flow (—0.2 0.2
ml min') and after death of the animal (—0.3 0.2 ml min)
and did not differ significantly from zero. RBF was expressed as
ml min g of kidney weight and hindquarter blood flow as
ml min 100 g' of body weight. Vascular resistances were
calculated by dividing the MAP by the simultaneous measure-
ments of blood flow to the kidneys or hindquarters.
Experimental protocols
Each experiment followed a similar plan. Groups of rats were
equilibrated to HS or LS diet, received a pretreatment and were
studied during a basal period, and during graded or maximal
infusions of L-NAME or vehicle. Rats of group lb were also
studied during graded intravenous infusions of SIN-i.
Group 1. The aim was to contrast the effects of dietary salt on
the dose-response relationships for systemic and renal hemody-
namic responses to graded intravenous doses of vehicle (group la)
or L-NAME (group ib). Preliminary studies were undertaken to
determine the threshold response and maximal doses for L-
NAME. During these studies, it was apparent that the MAP
became unstable during prolonged incremental infusions of L-
NAME. Therefore, two groups of HS and LS rats were infused
with L-NAME. The first group were studied during a basal period
and during infusion of L-NAME at 3.7, 37, and 370 nmol kg
min'. The second group was studied during a basal period and
during infusion of L-NAME at 11.11 mol kg' min. Since
baseline values were not different between the two HS and the two
LS groups, they were pooled for analysis. Separate groups of HS
and LS rats received vehicle infusions.
Group 2. Since L-NAME infusion appeared to increase the
MAP more in HS than LS rats, these studies were designed to
assess the effects of salt intake on the renal and hindquarter blood
flow responses to L-NAME independent of changes in perfusion
pressure. During surgery, a clamp [16] was placed around the
aorta above the origin of the renal arteries. After the basal period,
L-NAME was infused intravenously at 111, 370, and 11,100
nmol kg' .min for 30 minute periods. The femoral arterial
pressure was regulated each five minutes at a level equivalent to
that at the end of the basal period by adjustment of the aortic
clamp. The RBF and HQBF were recorded every five minutes.
Minimal values were obtained after 20 minutes of infusion.
Therefore, data were analyzed at this time period.
Group 3. The aim was to determine the effects of dietary salt on
the dose-response relationship for changes in PRA during graded
intravenous infusions of L-NAME without control of the renal
perfusion pressure. These animals were prepared as in group 1
with a laparotomy and dissection of the renal artery and terminal
aorta, except that RBF and HQBF were not measured. Arterial
blood samples (200 pA) were taken at the end of the basal period
and at the end of each dose of L-NAME for measurement of
PRA; samples were replaced with an equivalent volume of
albumin-in-saline solution (3 g' 100 m11). Using this replace-
ment protocol, the arterial blood hematocrit (Hct) at the end of
the study was 44.8 0.7% (N = 15). This is similar to the Hct
values of HS or LS rats prepared similarly for micropuncture [17],
but not subjected to blood sampling with albumin replacement
and L-NAME infusion. Blood samples were taken into EDTA-
containing tubes, centrifuged immediately and the plasma sepa-
rated and stored at —70°C for subsequent analysis. For this group,
rats received the full range of infusion of L-NAME (3.7, 37, 370,
and 11,110 nmol kg' .min).
Group 4. The aim was to determine whether differences in Ang
II generation in HS and LS rats governed the effects of dietary salt
on the renal and hindquarter hemodynamic responses to L-
NAME. Groups of rats received the angiotensin converting
enzyme (ACE) inhibitor captopril in the drinking water (25
mg 100 ml1) for three days prior to study. This resulted in a
daily captopril dose of 20 to 50mg kg. On the day of study, rats
received an additional bolus dose of captopril of 10 mg .kg1
given intravenously after anesthesia. Preliminary studies in rats
given bolus graded intravenous doses of Ang I demonstrated that
the expected dose of Ang Ito increase MAP by 30 mm Hg (ED30)
was 0.97 0.13 g kg (N = 7) in normal rats and increased
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fivefold (P < 0.05) in rats with this schedule of captopril admin-
istration in the drinking water to 4.9 1.6 ig kg (N = 4). For
this and subsequent groups, L-NAME was infused at the maximal
dose of 11 11 tmol kg min only.
Group 5. Since ACEI administration might modulate the
response to L-NAME infusion independent of its action to reduce
Ang II generation the aim of this study was to block Ang II by use
of a drug with a different mode of action. Group 1 of HS and LS
rats that received the Ang II type 1 (AT1) receptor antagonist
losartan in the drinking water (100 mg 100 ml) for three days
prior to study. This resulted in a losartan dose of 60 to 150
mg kg1 24 hr. On the day of the study, rats received an
additional bolus dose of intravenous losartan of 10 mg kg' with
surgery. Preliminary studies in rats given bolus i.v. doses of Ang II
showed that this schedule of losartan administration in the
drinking water significantly (P < 0.01) increased the ED30 from
0.4 0.1 (N = 11) in normal rats to 10.0 0.5 tg kg (N = 3)
in rats given losartan.
Chemical methods
The PRA was analyzed from the rate of generation of Ang I
over a 90 minute incubation period at 37°C using methods
described previously [18].
Drugs
NGnitroLarginine methyl ester was obtained from Sigma
Chemical Co., and dissolved in 0.154 M NaC1 solution. Captopril
was obtained from Bristol-Myers-Squibb Pharmaceuticals Inc.
(Princeton, New Jersey, USA) and was dissolved in drinking
water. Losartan was obtained from DuPont-Merck Pharmaceuti-
cals Inc., (Wilmington, Delaware, USA) and was dissolved in
0.154 M NaC1 solution. SIN-i was obtained from Cassella Ag
(Frankfurt/Main, Germany) and dissolved in 0.154 M NaCl solu-
tion. SIN-i was protected from exposure to light.
Statistical methods
Data are presented as mean SEM values. Some of the
perturbations were found to have altered the baseline data. The
absolute changes in RVR with L-NAME were dependent on the
baseline values of RVR (r = 0.43; N = 47; P < 0.005) but the
fractional changes were not significantly dependent (r 0.22; N =
47; NS). Therefore, we elected to analyze fractional changes in
response to L-NAME [i9J. Within group analyses were per-
formed using an unpaired Student's t-test and between group
analyses using an analysis of variance (ANOVA). Results are
considered significant if P < 0.05.
Results
Group 1
In the basal state, there were no significant differences between
the MAP, RBF, or HQBF of the HS and LS groups of rats.
Vehicle-infused rats showed no significant changes in any param-
eters. L-NAME induced graded pressor responses (Fig. iA) and
reduced the RBF and HQBF (Table i); this resulted in sharp
increases in RVR (Fig. 1B) and HQVR (Fig. 1C). At the highest
dose of L-NAME, there were greater fractional rises in MAP and
falls in RBF in HS than LS rats. Salt intake had consistent effects
on the changes in RVR with L-NAME; HS rats had a 70% greater
increase in RVR than LS rats during infusion of L-NAME at the
highest dose (Fig. 1B). In contrast, the increases in HQVR were
similar in both groups (Fig. 1C; Table 1).
Infusions of SIN-i into rats that had received L-NAME led to
graded and complete reversal of the increases in MAP, RVR and
HQVR. SIN-i caused comparable changes in RVR (Fig. 2A) or
HQVR (Fig. 2B) in HS and LS rats. There were no differences
between HS and LS rats in the MAP responses to SIN-i (data not
shown).
Group 2
Rats prepared with a suprarenal aortic clamp had basal values
for MAP, RBF and HQVR that were not significantly different
from those in group 1. The clamp was adjusted successfully in
each group to obviate any significant changes in perfusion pres-
sure during graded infusions of L-NAME. Both RBF and HQBF
appeared to be more responsive to L-NAME during control of
perfusion pressure than in the uncontrolled state. The graded
reductions in RBF with increasing doses of L-NAME were greater
in HS than LS rats at each dose (Fig. 3A), whereas the reductions
in HQBF were not different between the two groups at any dose
of L-NAME (Fig. 3B).
Group 3
In the basal state, the PRA was greater (P < 0.OOi) in LS than
HS rats (LS; 29.5 4.7 vs. HS; 8.07 1.82 ng Ang I ml1 hr1).
Infusion of L-NAME led to graded reductions in PRA that
paralleled the increases in MAP (Fig. 4A). Since the baseline
values of PRA were dependent on the salt intake, Figure 4B
depicts the fractional changes in PRA during L-NAME. It is
apparent that L-NAME led to equivalent fractional reductions in
PRA in HS and LS rats. In contrast, there were no significant
changes in the PRA of a group of vehicle-infused LS control rats
(APRA: —5.0 3.5 ng Ang I ml hr'; N = 7, NS).
Group 4
After captopril, the baseline values for MAP and RVR were
significantly lower in LS than HS rats (Table 1). However, as in
the rats that had not received captopril, the increment in RVR
produced by L-NAME was greater in HS than LS rats. After
captopril, the baseline values for HQVR were not significantly
altered and there were no differences in the HQVR response to
L-NAME between HS and LS rats.
Group 5
To determine whether the effects of captopril could be ascribed
to inhibition of Ang II generation, studies were undertaken in
groups of HS and LS rats given losartan in a similar dosing
schedule to captopril in group 4. As with captopril, losartan also
reduced the basal RVR but did not significantly modify the
fractional increases in RVR with L-NAME in either HS or LS
rats. After losartan, the fractional decrease in RBF and increase
in RVR with L-NAME remained greater in HS than LS rats,
whereas there were no effects of losartan on the fractional
changes in HQBF or HQVR with L-NAME. Thus, the effects of
losartan pretreatment on the response to L-NAME were qualita-
tively similar to the effects of captopril pretreatment.
Discussion
Infusion of maximal doses of NGmonomethylLarginine (L-
NMA) into anesthetized Sprague-Dawley rats causes a greater
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A
Effect of L-NAME: NS NS P<O.O1 P<O.OO1
B
Effect of L-NAME: NS NS P<O.001 P<o.oo1
Effect of salt on
response to L-NAME NS NS NS
Effect of salt on
NS response to L-NAME: NS
C
L-NAME (pmol/kg/min) or equivalent vehicle L-NAME (pmol/kg/min) or equivalent vehicle
Effect of L-NAME: NS NS NS P<O.OO1
0
Fig. 1. Mean SEM values for fractional changes in mean arterial pressure
(A), renal vascular resistance (B) and hindquarter vascular resistance (C)
during graded intravenous doses of vehicle (group la; square symbol and
___________________________________
broken lines) orL-NAME (group ib; round symbols and continuous lines) in
'
rats equilibrated to high salt (solid symbols) or low salt (open symbols) diets.0.01 0.1 1 1 0 100 Data were analyzed by analysis of variance and results are presented for
the effects of L-NAME compared to vehicle and the effects of dietaty salt
L-NAME (pmol/kg/min) or equivalent vehicle on the response to L-NAME.
pressor response in those adapted to a high salt diet [201. Our
results confirm the rather greater pressor response in HS than LS
rats during maximal doses of L-NAME. Schultz and Tolins [61
demonstrated that salt-loaded rats had enhanced renal hemody-
namic responses to intrarenal L-NMA, compared to rats on a
normal salt intake. These results were confirmed in the present
study in which NOS was inhibited with intravenous L-NAME. The
present study demonstrated further that the effects of dietary salt
on the vascular responsiveness to NOS inhibition were not
uniform. Thus, HS led to a marked potentiation of the renal
vasoconstrictor response to L-NAME without modifiing the
hindquarter response. Renal autoregulation remains intact after
NOS inhibition in the rat [31. However, these effects of dietary salt
on the vasoconstrictor responses were not simply autoregulatory
adjustments to the rather greater increase in renal perfusion
pressure in HS rats, since these rats had a greater maximal
reduction in RBF than LS rats, despite the greater increase in
blood pressure. To fully dissociate any effects of changes in
perfusion pressure on salt-induced changes in vascular resistance,
separate groups of rats were studied while the perfusion pressure
to the kidneys and hindquarters was maintained with a suprarenal
aortic clamp. In these rats, the reductions in RBF with L-NAME
were greater in HS than LS rats whereas the reductions in HQBF
remained similar in each group. We conclude that a high salt
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Table 1. Body weight, mean arterial pressure, renal blood flow, renal vascular resistance, hind-quarter blood flow and hind-quarter vascular
resistance in groups of rats equilibrated to high salt and low salt diets and fractional changes produced by L-NAME infusion
MAP RBF RVR HQBF
HQVR
Basal
No. Body with Basal with Basal with Basal with mm Hg! with
Group of wt Basal L-NAME mi/mm! L-NAME mm Hg! L-NAME mi/mm! L-NAME mi/mm! L-NAME
(Pretreatment) rats g mm Hg % g % milminig % 100 g % 100 g %
No pretreatment
HS 10 304±10 123±5 +32±4 8.1±0.6 —47±3 15.8±1.1 +159±18 4.2±0.3 —46±4 29.8±1.9 +151±12
LS 9 294±7 125±5 +22±3 7.5±0.7 —32±4 17.5±1.2 +83±10 3.9±0.4 —51±4 33.8±2.8 +161±19
HS vs. LS NS P = 0.05 NS P < 0.01 NS P < 0.005 NS NS NS NS
Captopril
HS 8 302±12 107±5 +47±5 9.6±0.9 —40±2 11.6± 1.0 +150±13 3.3±0.4 —35±7 34.7±2.9 +141±23
LS 7 268±12 94±5 +42±4 10.7±1.0 —23±5 9.0±1.0 +87±8 3.3±0.4 —43±2 31.1±5.0 +150±12
HS vs. LS NS NS NS P < 0.005 P < 0.05 P < 0.005 NS NS NS NS
Losartan
HS 7 290±5 99±4 +43±3 9.4±0.7 —44±4 10.8±0.7 +164±19 5.7±0.4 —36±4 17.8±1.3 +131±16
LS 6 281±12 93±4 +40±3 9.5±0.6 —33±4 10.1±1.0 +112±12 4.5±0.4 —31±4 21.1±1.7 +104±9
HS vs. LS NS NS NS P < 0.05 NS P < 0.05 NS NS NS NS
Mean SEM values for basal data and fractional changes produced by infusion of L-NAME at 11.11 j.g kg1 min1.
intake enhances the vascular reactivity to L-NAME specifically in
the kidneys. This effect is independent of changes in perfusion
pressure.
The pressor response to L-NAME in conscious rats is accom-
panied by a decrease in renal and hindquarter blood flow and a
decrease in cardiac output [21]. The present studies confirm the
presence of intense renal and hindquarter vasoconstriction in
anesthetized rats infused with L-NAME and show further that this
can be reversed in full by the NO donor, SIN-i. SIN-i caused
similar hemodynamic changes in HS and LS rats. This suggests
that the enhanced renal vasoconstrictor response to inhibition of
NOS in HS rats was not due to an enhanced responsiveness of the
renal circulation to NO and therefore more likely entails an
enhanced NO generation. This is consistent with the finding that
dietary salt loading enhances the excretion of the NO metabolites,
NO2 and NO3 and of cGMP which is an index of the action of NO
on target tissues [6]. The present findings indicate that these
effects of dietary salt on NO generation are specific for the
kidneys since the hindquarter vascular response to NOS inhibition
was independent of dietary salt intake. Our preliminary studies
have disclosed that an HS diet promotes a NO signalling pathway
between the macula densa and the afferent arteriole [22]. This
salt-sensitive vasodilator pathway might contribute to salt-sensi-
tive generation of NO by the kidney. However, the present
findings do not identify the location of the NOS that is responsible
for relating whole-kidney hemodynamics to changes in dietary
salt.
The renin-angiotensin system mediates many of the renal
adaptive responses to changes in dietary salt. Moreover, there are
strong interactions between Ang II and NO in the kidneys. Thus,
inhibition of NOS potentiates and prolongs the contractile re-
sponse to Ang II on the isolated rabbit afferent arteriole [2]
whereas afferent and efferent arterioles harvested from rats
pretreated with Ang II blockers exhibit less vasoconstriction with
N'3-nitro-L-arginine (L-NA) [4]. Therefore, we designed studies
to investigate the role of Ang II in mediating the effects of dietary
salt on the renal vascular responsiveness to NOS inhibition. Since
we found that L-NAME reduced the PRA of HS and LS rats, it
seemed unlikely that changes in renin release could explain the
effects of salt intake on the renal vascular response to L-NAME in
our study. However, NOS inhibition has complicated effects on
renin secretion. In an isolated JGA cell system, NO donors cause
an abrupt reduction in renin release into the supernatant followed
by a sustained increase. In whole animal studies, short-term
intravenous infusions of L-NAME at pressor doses normally
suppresses PRA [11], as in the present study. However, after
control of the renal perfusion pressure and blockade of the effects
of renal nerve activity by a 13-receptor antagonist, L-NAME
stimulates PRA [11]. Likewise, renal tissue Ang II concentrations
are reduced during infusion of L-NA at pressor doses but are
increased during L-NA infusion with control of the RPP [3].
Studies of renal tissue Ang II levels have shown that they may be
dissociated from changes in PRA during NOS blockade [3].
Therefore, we elected to study the role of Ang II in mediating
salt-dependent changes in RVR with L-NAME more directly by
blockade of Ang II generation with three days of captopril
administration or of AT1 receptors with three days of losartan
administration. The dosing schedules for captopril and losartan
were found to blunt the pressor responses to Ang I and Ang II,
respectively. Moreover, both of these drugs reduced the BP and
RVR; these effects were most prominent in LS rats, which
indicates that they were effective in blocking Ang II generation or
action within the kidneys. After captopril or losartan, the reduc-
tion in RBF and the increase in RVR with L-NAME remained
greater in HS than LS rats whereas there was no effect of dietary
salt on the changes in HQBF or HQVR. These data indicate that
the specific renal effects of dietary salt on the response to
L-NAME are not dependent on changes in Ang II generation or
AT1 receptor activation.
Short-term administration of ACEI's does not alter release of
endothelium-derived relaxing factor from isolated vessels [23], but
may have effects in vivo mediated by changes in blood flow that
alters the vessel wall shear stress [24]. Sigmon et al [7, 8] found
that blockade of AT1 receptors with losartan or of ACE with
enalaprilat prevented the increase in RVR during L-NAME
infusion. Tolins and Raij [9] and Takenaka, Mitchell and Navar
[31 used a peptide Ang II antagonist or losartàn respectively and
found a blunting of the renal vasoconstrictor response to L-NMA
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Effect of salt: NS NS NS NS NS
SIN-i, pmol/kg
Fig. 2. Mean SEM values from rats of group lb that received a constant
intravenous infusion of L-NAME at 11.11 .unol kg1 min' without
control of the perfusion pressure. Data depict the fractional changes in renal
vascular resistance (A) and hindquarter vascular resistance (B) during
graded intravenous bolus injections of SIN-i in groups of high salt (solid
symbols) and low salt (open symbols) rats. Compared to results before
SIN-i infusion: *P < 0.05; ** < 0.01; 4"P < 0.005.
0.1 1 10
Fig. 3. Mean SEM values for changes in renal blood flow (A) or
hindquarter blood flow (B) during graded intravenous infusions of L-NAME
in groups of high salt (solid symbols) and low salt (open symbols) rats whose
renal and hindquarter perfusion pressures were regulated at basal values by
adjustment of a suprarenal aortic clamp. Compared to basal: ** < 0.01;
***p < 0.005.
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or L-NA. Pucci, Lin and Nasjletti [12] studied the increases in
RVR induced by L-NA in the rat. They detected no effects of
captopril, given alone or in combination with indomethacin and
chiorisondamine to block ACE, ganglionic transmission and cy-
clooxygenase together. Recently, Baylis et al [13] have reported
that Ang II plays no role in renal vasoconstriction after NOS
inhibition in conscious rats. Ang II appears to be less important in
determining the renal vascular response to NOS inhibition in
conscious rats [14]. The reason for these variable results is not
clear. However, the absence of a role for Ang II in determining
the renal vascular response to inhibition of NOS in the present
study cannot be ascribed to anesthesia since these results in
anesthetized rats are similar in this regard to results in conscious
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NS NS NS
Fig. 5. Mean SEM values for fractional changes in renal vascular resistance
(panel A) or hindquarter vascular resistance (B) in groups of rats adapted to
high salt () or low salt (E') diets in response to intravenous infusion of
L-NAME at 11.11 p.inol kg1 mm without control of perfusion pressure.
Abbreviations are: Control, no pretreatment; Cap, 3 days of captopril
administration in the drinking water and bolus intravenous captopril with
surgely on the study day (group 4); LOS, 3 days of losartan administration
in the drinking water and bolus IV losartan with surgery on the study day
(group 5).
L-NAME, pmol/kg/min
Fig. 4. Mean SEM values for plasma renin activity (PRA; A) or fractional
changes (B) during intravenous infusions of L-NAME (group 2) in groups of
high salt (solid symbols) and low salt (open symbols) rats whose renal
perfusion pressure was not controlled. Compared to baseline: *P < 0.05;
***p < 0.005.
rats [121. Nor are the results readily explained by differences in the
baseline values for PRAsince captopril or losartan did not modify
the RVR response to L-NAME in HS rats whose basal value for
PRA were less than 30% of the value of LS rats. One possible
explanation for the different conclusion from the present study is
the experimental condition. In this study, the drugs were given for
three days prior to testing.
In conclusion, dietary salt intake modulates the renal, but not
the hindquarter, vascular response to inhibition of NOS. A
selective increase in NO generation in the kidneys during a high
salt intake may be important for homeostasis by diverting blood
flow to the kidneys, maintaining or increasing the GFR, blunting
the tubuloglomerular feedback response [5], and inhibiting NaCI
reabsorption by the thick ascending limbs of the loop of Henle
[25]. A high salt intake appears to increase renal NO generation
largely independent of the effects of Ang II generation.
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